The PCROWD Study invites people with precursor conditions to Share samples a few times each year

The PCROWD Study invites people with precursor conditions to Share samples a few times each year when they are collected as part of routine follow up care.

Update 63rd ASH Annual Meeting: Non-Invasive Liquid Biopsy - Circulating Multiple Myeloma Cells

78 Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease PathologyClinically Relevant Abstract

Program: Oral and Poster Abstracts

Type: Oral

Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational I

Hematology Disease Topics & Pathways:

Fundamental Science, Translational Research, Clinically Relevant

Saturday, December 11, 2021: 10:45 AM

Conclusion:

Our results demonstrate clinical correlation and molecular characterization of CMMCs from MGUS/SMM patients. This study provides a foundation for non-invasive detection, enumeration and genomic interrogation of rare CMMCs from the peripheral blood of MGUS/SMM, illustrating the clinical potential of using liquid biopsies for monitoring and managing disease in the precursor setting of MM.

https://ash.confex.com/ash/2021/webprogram/Paper150622.html

---

The PCROWD Study

invites people with precursor conditions to share samples a few times each year when they are collected as part of routine follow up care. Allow us to track changes that occur in their samples and medical record

OUR STUDY'S GOAL

We aim to track 10,000 individuals with early stages of blood cancer or precursor conditions which include (in alphabetical order):

• Clonal Hematopoiesis of Indeterminate Potential (CHIP)

• Monoclonal B cell Lymphocytosis (MBL)

• Myelodysplastic Syndrome (MDS